Wells Fargo & Company Cuts Insmed (NASDAQ:INSM) Price Target to $160.00

Insmed (NASDAQ:INSM) had its price objective reduced by Wells Fargo & Company from $177.00 to $160.00 in a report issued on Friday morning, MarketBeat Ratings reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on INSM. Roth Mkm reaffirmed a “buy” rating and set a $212.00 price target on shares of Insmed in a research note on Friday, April 17th. Truist Financial set a $205.00 price target on Insmed in a research note on Monday, January 12th. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Guggenheim cut their price target on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research note on Friday. Finally, Stifel Nicolaus lifted their price target on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $211.86.

Insmed Trading Down 0.2%

NASDAQ:INSM opened at $101.17 on Friday. The company has a market capitalization of $21.93 billion, a PE ratio of -17.60 and a beta of 0.89. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. Insmed has a 52-week low of $64.85 and a 52-week high of $212.75. The stock has a fifty day simple moving average of $145.87 and a 200-day simple moving average of $165.46.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business’s revenue was up 229.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.42) EPS. On average, equities research analysts expect that Insmed will post -2.41 earnings per share for the current fiscal year.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. The trade was a 45.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $43,361,604.45. The trade was a 3.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 161,193 shares of company stock valued at $25,462,012. 2.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CoreCap Advisors LLC acquired a new position in Insmed in the 4th quarter valued at about $27,000. Reflection Asset Management acquired a new position in shares of Insmed during the 4th quarter valued at about $30,000. GraniteShares Advisors LLC acquired a new position in shares of Insmed during the 4th quarter valued at about $30,000. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of Insmed during the 4th quarter valued at about $32,000.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.